Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (4): 423-426.doi: 10.12092/j.issn.1009-2501.2024.04.009

Previous Articles     Next Articles

Value of biotargeted drugs in airway mucus therapy of asthma

MOU Duo1, LIU Kexin1,2, CHANG Chun1   

  1. 1Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100080, China; 2Department of Respiratory and Critical Care Medicine, Wuhan First Hospital, Wuhan 430030, Hubei, China
  • Received:2023-09-05 Revised:2023-11-02 Online:2024-04-26 Published:2024-03-25

Abstract:

Airway mucus plug is a common phenotype in asthma that increases the risk of acute asthma attacks by causing aggravation of airflow obstruction. Given its important role in asthma, treatment targeting airway mucus plugs may be a strategy to control asthma progression and prevent fatal asthma exacerbations. Previous studies have shown that acidosophils and T2 type inflammation are related with the formation of mucus plugs, and biotargeted drugs targeting the above pathways may be effective in the treatment of airway mucus plugs.

Key words: airway mucus, asthma, biotargeted drugs

CLC Number: